Current Medicinal Chemistry
Title:Meet Our Editorial Board Member:
Volume: 22 Issue: 28
Author(s): Lakshmi P. Kotra
Affiliation:
Export Options
About this article
Cite this article as:
P. Kotra Lakshmi, Meet Our Editorial Board Member:, Current Medicinal Chemistry 2015; 22 (28) . https://dx.doi.org/10.2174/092986732228150929141246
DOI https://dx.doi.org/10.2174/092986732228150929141246 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
17
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phosphodiesterase Type 5 Inhibitors for the Management of Erectile Dysfunction: Preference and Adherence to Treatment
Current Pharmaceutical Design Prediction of Cardiovascular Risk Using Extreme Learning Machine-Tree Classifier on Apache Spark Cluster
Recent Advances in Computer Science and Communications Polymeric Materials and Formulation Technologies for Modified-Release Tablet Development
Mini-Reviews in Medicinal Chemistry Advantages of Nanotechnology- Based Chinese Herb Drugs on Biological Activities
Current Drug Metabolism Indandione and Its Derivatives - Chemical Compounds with High Biological Potential
Mini-Reviews in Medicinal Chemistry Evaluating a Child with Partial Developmental Delay (ParDD), Global Developmental Delay (GDD)/Mental Retardation (MR): Clinical Expertise Based or Evidence-Based?
Current Pediatric Reviews Diagnosis and Prognosis of Fetal Cardiomyopathies: A Review
Current Pharmaceutical Design Recent Advances in the Synthesis of 1,3-Azoles
Current Topics in Medicinal Chemistry The Gastrin-Releasing Peptide Receptor as a Therapeutic Target in Central Nervous System Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Bioactivity of Exogenous Cytoskeleton Proteins: Regulation of Development of Plant Microspores as Biosensors
Current Bioactive Compounds The Synthetic Cannabinoids Phenomenon
Current Pharmaceutical Design Seeing the Person in the Patient: Making the Case for Individualized PROMs in Mental Health Care
Current Psychiatry Reviews α7-Nicotinic Receptors and Cognition
Current Drug Targets Peptide Mimetics of Neurotrophins and their Receptors
Current Pharmaceutical Design Cannabis Epidemiology: A Selective Review
Current Pharmaceutical Design Development of Novel Genomic Blood Biomarkers for Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Single Heterocyclic Compounds as Monoamine Oxidase Inhibitors: From Past to Present
Mini-Reviews in Medicinal Chemistry Genetics of Anxiety Disorders - Status Quo and Quo Vadis
Current Pharmaceutical Design Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer,s Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
Current Alzheimer Research Editorial (Thematic Issue: Novel Perspectives for Parkinson’s Disease Therapy: Insights from the Latest Advances in Disease Pathophysiology, Diagnostic and Experimental Tools and Molecular Targets)
CNS & Neurological Disorders - Drug Targets